{
"@context": "https://schema.org",
"@type": "Project",
"datePublished": "2021-07-01",
"dateModified": "2025-03-04",
"name": "Immunotherapy and targeted therapy of advanced non-small cell lung carcinoma: Treatment benefits and cost in an unselected real-life population",
"headline": "Immunotherapy and targeted therapy of advanced non-small cell lung carcinoma: Treatment benefits and cost in an unselected real-life population",
"author": "Folkehelseinstituttet",
"image": "Model.MainImage.GetImageUrl()",
"hideImage":"False",
"publisher": {
"@type": "Organization",
"name": "Folkehelseinstituttet",
"logo": {
"@type": "ImageObject",
"url": "https://www.fhi.no/contentassets/c03aa76fe30941f08474ee823ba2a928/logo-norsk-hel-navnet-uten-luft-rundt.png"
}
}
}
Immunotherapy and targeted therapy of advanced non-small cell lung carcinoma: Treatment benefits and cost in an unselected real-life population
About the project
-
Project period:
01.07.2021 - 31.12.2024
(Concluded)
-
Coordinating Institution:
Norwegian Institute of Public Health
-
Project Manager:
-
Bettina Kulle Andreassen, The Cancer Registry of Norway, Norwegian Institute of Public Health
-
Project Participants:
- Helga Helseth Hektoen, The Cancer Registry of Norway, Norwegian Institute of Public Health
- Giske Ursin, The Cancer Registry of Norway, Norwegian Institute of Public Health
-
Published
|
Last update